Optogenetic Neural Progenitor Cells for Controlled Spinal Cord Repair

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for nervous system damage lack direct control over transplanted cells and are not effective in repairing or regenerating injured or diseased nervous tissue.

Innovation Solution

Development of optogenetically-activatable neural progenitor cells that can be engineered to respond to light stimuli, allowing precise control over their activity and integration into the nervous system, enhancing repair and regeneration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If traditional cell transplantation is used to repair nervous system damage, then cells can be transplanted into the injured tissue, but the transplanted cells cannot be directly controlled or activated to produce therapeutic effects

Engineering Contradiction:

Improvecontrol over transplanted cellsVSAvoidtherapeutic effect production

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent replaces traditional chemical pharmacologic activation with optogenetic control using light stimuli. Light-sensitive ion channels (such as channelrhodopsin) are expressed in transplanted neural progenitor cells, allowing direct optical control of cell activity without relying on spontaneous mechanisms or chemical drugs, thus achieving precise control while maintaining reliable therapeutic effect production

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent modifies the physiological state of transplanted cells by introducing light-sensitive components, changing the control parameter from chemical signaling to optical signaling. This enables external control of cell activity through light delivery, transforming the cells from uncontrollable transplants to programmably activatable therapeutic cells

Inventive Principle:

Principle #35Parameter changes

2Reliability

If spontaneous mechanisms are relied upon for cell activation after transplantation, then no direct control is needed, but therapeutic effects are not reliably produced or are insufficient

Engineering Contradiction:

Improvetherapeutic effect productionVSAvoidcontrol over transplanted cells

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent substitutes reliance on spontaneous chemical signaling with direct optical control. By expressing light-sensitive ion channels in transplanted neural progenitor cells, the system enables precise, on-demand activation of cells through light delivery, dramatically improving the reliability and controllability of therapeutic effect production

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The optogenetic system provides a controllable feedback mechanism where light stimuli directly modulate cell activity. This allows real-time control and monitoring of transplanted cell function, enabling therapeutic effects to be produced reliably and controllably based on external optical signals

Inventive Principle:

Principle #23Feedback

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The cells demonstrate anatomical and functional connectivity, improving motor recovery and muscle function by integrating with injured spinal cord circuits and responding to light activation.

Implementation Method 1

engineered, neural progenitor cells having a response to an optogenetic stimulus that increases or decreases cell activity

Methodology Applied

Scientific EffectOptogenetic response: Photoelectric Effect

Data Source

PatentUS20250230408A1Methods and compositions for optogenetically engineered cells for neural repair

Publication Date: 2025.07.17 THE J DAVID GLADSTONE INSTITUTES

AI summary

Compositions and methods for administering optogenetically-activatable cells for repair of the nervous system after injury or disease are contemplated herein.